Evidence mapPaperPMID 41268622Full record

ReviewJournal of diabetes science and technology2025

Expert Opinion Statement on Continuous Glucose Monitoring in Type 2 Diabetes in the Arab Gulf Region.

Abdulrahman Alshaikh, Abdulmohsen Bakhsh, Afaf Al-Sagheir, Ahmed El-Laboudi, Dabia Al-Mohanadi, Fatheya Al Awadi, Hussein Elbadawi, Lamya Alzubaidi, Mohammed E Al-Sofiani, Muhammad Hamed Farooqi and 4 more

Abstract readReview
In one paragraph

Review in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Abdulrahman AlshaikhKing Abdulaziz University, Jeddah, Saudi Arabia.
Abdulmohsen BakhshKidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Afaf Al-SagheirCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Ahmed El-LaboudiImperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
Dabia Al-MohanadiQatar Metabolic Institute, Hamad Medical Corporation, Doha, Qatar.
Fatheya Al AwadiMohammed Bin Rashid University, Dubai Health, Dubai, United Arab Emirates.
Hussein ElbadawiMetabolic Unit, My Clinic International, Jeddah, Saudi Arabia.
Lamya AlzubaidiMinistry of Health, Riyadh, Saudi Arabia.
Mohammed E Al-SofianiDivision of Endocrinology, Department of Internal Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.ORCID 0000-0003-4420-9378
Muhammad Hamed FarooqiDubai Diabetes Center, Dubai Health, Dubai, United Arab Emirates.
Raed AldahashKing Saud bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia.
Reem AlamoudiKing Saud bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia.
Saud AlsifriEndocrinology Department, Alhada Armed Forces Hospital, Taif, Saudi Arabia.
Mohammed AlmehthelObesity, Endocrinology and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.ORCID 0000-0002-4031-881X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The introduction of continuous glucose monitoring (CGM) has been considered a transformative monitoring tool in diabetes management. However, its adoption remains limited in the Gulf region, especially for patients with type 2 diabetes, due to cost, lack of reimbursement strategies, variability in healthcare infrastructure, and lack of trained health care providers (HCPs). The lack of regional guidelines tailored to the unique demographic, cultural, and health care needs of the Gulf population has resulted in low adoption and inconsistent use of CGM in clinical practice, leaving many patients without adequate advanced glucose monitoring options. This expert opinion statement evaluates the evidence for real-time CGM in the management of patients with type 2 diabetes and provides region-specific recommendations to guide HCPs in optimizing CGM use, improving patient outcomes, and addressing barriers to implementation in the Gulf region.

Indexed as

expert opinionintensive insulin therapyreal-time continuous glucose monitoringthe Gulf regiontype 2 diabetes

Identifiers

PMID41268622
PMCPMC12638232

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.